ISL
CPRX

Ingalls & Snyder LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

Ingalls & Snyder LLC’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,000
Closed -$105K – 443
2022
Q2 		$105K Buy
+15,000
New +$110K 0.01% 423

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ingalls & Snyder LLC's CPRX Position: Q3 2022 in Review

Ingalls & Snyder LLC sold out of Catalyst Pharmaceutical (CPRX) in Q3 2022, closing a stake of 15,000 shares — an estimated $105K sold.

Ingalls & Snyder LLC first reported a position in CPRX in Q2 2022 and held it in 1 quarter. The position peaked at $105K in Q2 2022. 229 funds tracked by Wall St. Rank hold CPRX as of Q3 2022.

  • Ingalls & Snyder LLC reported no remaining Catalyst Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 15,000 Catalyst Pharmaceutical shares in Q3 2022, an estimated $105K.
  • Ingalls & Snyder LLC first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 1 quarter.
  • Ingalls & Snyder LLC's Catalyst Pharmaceutical position peaked at $105K in Q2 2022.
  • 229 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2022.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2022, filed 21 Oct 2022.